ALK and ARS Pharmaceuticals sign a deal giving ALK global rights to Neffy nasal spray outside key regions, targeting peak sales of around $400 million in anaphylaxis treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback